Advances in Quinazolinone‐Based Tumor‐Targeted Inhibitors
Chemistry & Biodiversity · 2026-06 · 23 (6)
DOI: 10.1002/cbdv.71413 ↗At a glance
Übersichtsarbeit in Chemistry & Biodiversity, published online on 2026-06-11. Written by Jieming Li and 8 co-authors. Institution: Henan University of Chinese Medicine, Zhengzhou, China. Major MEDLINE topics: Quinazolinones, Antineoplastic Agents, Neoplasms, Protein Kinase Inhibitors. 91 references. Funded by: China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (original language)
Quinazolinone derivatives, characterized by their unique heterocyclic scaffold and extensive structural tunability, hold considerable promise as targeted antitumor agents. This review systematically summarizes recent advances in the antitumor pharmacology, multifaceted mechanisms of action, and target inhibitor development of this compound class. Mechanistically, quinazolinone derivatives exert antitumor effects through multiple pathways, most prominently the potent inhibition of tyrosine kinases (e.g., EGFR and VEGFR), which is supported by extensive preclinical and clinical evidence. Additional mechanisms include downregulation of the PI3K/AKT/mTOR signaling axis, disruption of cell cycle progression, and interference with epigenetic regulatory proteins. These actions collectively lead to the blockade of tumor cell proliferation signals, induction of mitochondrial‐dependent apoptosis, and attenuation of tumor angiogenesis and metabolic reprogramming. Structure–activity relationship (SAR) studies show that adding specific substituents boosts both target selectivity and pharmacokinetic properties. Notably, novel derivatives with dual‐target synergy inhibit tumor growth and overcome drug resistance, offering new strategies against tumor heterogeneity.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Henan University of Chinese Medicine, Zhengzhou, China.
- Henan Key Laboratory of Chinese Medicine for Polysaccharides and Drugs Research, Zhengzhou, China.
- Hefei Food and Drug Safety Inspection and Testing Center, Hefei, China.
- The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
ORCID profiles: Yuanfang Kong
Funding
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Cite
APA
Li, J., Lv, S., Yang, B., Ran, R., Kong, Y., Cai, J., Nan, G., Jiang, S., & Dong, C. (2026). Advances in Quinazolinone‐Based Tumor‐Targeted Inhibitors. Chemistry & Biodiversity, 23(6). https://doi.org/10.1002/cbdv.71413
Vancouver
Li J, Lv S, Yang B, Ran R, Kong Y, Cai J, et al. Advances in Quinazolinone‐Based Tumor‐Targeted Inhibitors. Chemistry & Biodiversity. 2026;23(6). doi:10.1002/cbdv.71413
BibTeX
@article{Li2026,
author = {Li, Jieming and Lv, Shuaiyi and Yang, Bin and Ran, Ruiping and Kong, Yuanfang and Cai, Juntao and Nan, Guanglei and Jiang, Shiqing and Dong, Chunhong},
title = {Advances in Quinazolinone‐Based Tumor‐Targeted Inhibitors},
journal = {Chemistry & Biodiversity},
year = {2026},
volume = {23},
number = {6},
doi = {10.1002/cbdv.71413}
}
EUVIMED